Open AccessC-105 Clinical trial of HER2 cancer vaccine shows benefit in 45% of evaluable patients in phase I study
Author(s) -
Jay A. Berzofsky,
Lauren V. Wood,
Hoyoung Maeng,
Jane B. Trepel,
David F. Stroncek,
John C. Morris
Publication year - 2019
Publication title -
journal of acquired immune deficiency syndromes
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.162
H-Index - 157
eISSN - 1944-7884
pISSN - 1525-4135
DOI - 10.1097/01.qai.0000557959.74614.41
Subject(s) - medicine , trastuzumab , pertuzumab , oncology , cancer , colorectal cancer , kras , immunohistochemistry , clinical trial , her2/neu , breast cancer